Clinical Trial Update: Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study [Phase 3]

View source ↗

Summary

This is a Phase 3 trial extension evaluating the long-term safety of the intravitreal axitinib implant (OTX-TKI) in participants with neovascular age-related ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• OTX-TKI Axitinib Implant (axitinib)

Snippet

Sponsor: Ocular Therapeutix, Inc. | Conditions: Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 | Status: NOT_YET_RECRUITING